CD28 x TAA-2 targeting bispecific antibody - Rondo Therapeutics
Latest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator Rondo Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Ovarian cancer
Most Recent Events
- 17 Oct 2024 Early research in Ovarian cancer in USA (Parenteral) before October 2024 (Rondo Therapeutics pipeline, October 2024)